Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer s Disease Trial Update
- Data Safety Monitoring Board confirms Bryostatin-1 Safety
News provided by
Share this article
Share this article
NEW YORK, June 9, 2021 /PRNewswire/ Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update on its ongoing National Institutes of Health ( NIH ) sponsored Phase 2b clinical trial of Bryostatin-1 in patients suffering from moderately severe Alzheimer s disease ( AD ). To date, the Company has now dosed 58 of its target 100 patients. Seventeen sites continue to be live.
Additionally, the independent Data Safety Monitoring Board ( DSMB ) overseeing the trial convened to assess the safety of Bryostatin through an interim analysis and confirmed that 40 advanced AD patients have been dosed with Bryostatin without any significant safety issues.
Synaptogenix Announces Phase 2b Bryostatin-1 Clinical Trial Update prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Synaptogenix to Present at Upcoming Scientific Industry Conferences
News provided by
Share this article
Share this article
NEW YORK, Feb. 25, 2021 /PRNewswire/ Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it will attend two upcoming scientific industry conferences.
On Thursday, February 25
th, Dr. Daniel Alkon M.D., President and Chief Scientific Officer, will present a virtual poster at the 9
th annual Neurodegenerative Drug Development Summit. The virtual posters begin at 5pm ET and the Synaptogenix presentation can be accessed via the following link.
th at 10am ET, Dr. Daniel Alkon M.D. will present at the 15
Synaptogenix to Present at Upcoming Scientific Industry Conferences prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.